Adherex Technologies Inc., today announced that it has received feedback from the FDA at an End-of-Phase 2 meeting held yesterday. During the FDA meeting, Adherex reviewed the opportunity that eniluracil offers to Metastatic Breast Cancer patients who had rapid disease progression on capecitabine. Adherex proposed a small pivotal single arm clinica
CAMBRIDGE, Mass., May 24, 2013 Aegerion Pharmaceuticals, Inc., an emerging biopharmaceutical company focused on the development and commercialization of novel therapeutics to treat debilitating and often fatal rare diseases, announced today that the company will participate in the Deutsche Bank 38th Annual Health Care Conference in Boston.
Alnylam Pharmaceuticals, Inc., a RNAi therapeutics company, announced that management will present a company overview at the Deutsche Bank 38th Annual dbAccess Health Care Conference on May 29, at 2:50 p.m. ET at The Westin Boston Waterfront Hotel in Boston. According to a release, a live audio webcast of the presentation will be available on the N
TOKYO& SAN FRANCISCO Astellas Pharma Inc. and Medivation, Inc. today announced that Astellas has submitted an application for marketing approval of enzalutamide to the Ministry of Health, Labour and Welfare in Japan for the treatment of prostate cancer. This filing application is based mainly on results obtained from the global Phase 3 trial* a
Auxilium Pharmaceuticals, Inc. today announced that executive management will participate in the Deutsche Bank Health Care Conference to be held May 29-30 at the Westin Boston Waterfront Hotel. About Auxilium Auxilium Pharmaceuticals, Inc. is a specialty biopharmaceutical company with a focus on developing and marketing products to predominantly...
Release date- 23052013- Lausanne, Switzerland and Dresden, Germany- Cenix BioScience, a leading preclinical contract research provider and technology developer specialized in RNAi-, miRNA- and high content-driven pharmacology, and Debiopharm Group, a Swiss-based global biopharmaceutical group of companies with a focus on the development of prescrip
China Biologic Products, Inc., a leading fully integrated plasma-based biopharmaceutical company in China, today announced that the Company has recently learned from a public announcement issued by Shanghai RAAS Blood Products Co., Ltd., a public company listed on Shenzhen Stock Exchange,... China Biologic Products, Inc., a leading fully integrated
Elixir Medical Corporation, a developer of products that combine state-of-the-art medical devices with advanced pharmaceuticals, announced today excellent long-term results of its CE Mark-approved DESyne BD Novolimus Eluting Coronary Stent System with biodegradable polymer coating compared to the control Endeavor Zotarolimus Eluting...
By a News Reporter-Staff News Editor at Health& Medicine Week Masimo announced that its rainbow Acoustic Monitoring? sensor, RAS-125c Acoustic Respiration Cloth Sensor has received U.S. FDA 510 clearance for continuous, noninvasive monitoring of acoustic respiration rate in pediatric patients. Masimo rainbow Acoustic Monitoring noninvasively an
Mumbai: An' import alert' by the US Food and Drug Administration on one of its plants is likely to cause a sales loss of $100 million or over Rs550 crore, Wockhardt said. The FDA has expressed concern on the drugmaker's export-oriented facility in Aurangabad. Analysts familiar with the development had said that the company was issued FDA 483 letter
Dublin- Research and Markets has announced the addition of the " Generic Pharmaceuticals" report to their offering. Despite the Global Generic Pharmaceutical industry becoming increasingly competitive there are 42 vibrant companies across the World exploiting innovative, more profitable routes to market. Just published the Plimsoll Global Analysis-
The government on Thursday issued new guidelines for Indian drug makers that are in compliance with a European Union directive on standards for import of bulk drugs into the EU. "India has demonstrated its keenness to meet international requirements for exports of pharmaceutical products yet again by taking timely action for complying with the new
The Icahn School of Medicine at Mount Sinai has granted Cellular Dynamics International exclusive license rights to commercially develop cardiomyocyte progenitors for in vivo cell therapy and regenerative medicine applications. The licensed technology is based on research first conducted by Gordon Keller, PhD, a former Professor of Gene and Cell...
Impax Laboratories, Inc. today announced that the Company will present at the Deutsche Bank 38 th Annual Health Care Conference on Thursday, May 30, at 12:00 p.m. Eastern Standard Time. Impax markets its generic products through its Global Pharmaceuticals division and markets its branded products through the Impax Pharmaceuticals division.
Some 6,000 diabetics have refused to use Wosulin drug made by the India- based company, Wockhardt Limited, resolving to find other optional medicines to survive. The medicine is still on trial, therefore we fear for our lives, "said Waziri Said Othman, chairman of the Diabetes Association of Zanzibar, adding:. "We cannot use the medicine until we
Infinity Pharmaceuticals, Inc. will be presenting at Deutsche Bank's 38th Annual Health Care Conference on May 29 at 4:15 p.m. ET in Boston. A live webcast of Infinity's presentation will be accessible on the "investors/media" section of the company's website, infi.com, and will be available for 30 days following the event. Infinity is a biopharmac
Release date- 23052013- New Brunswick, N.J.- At a meeting today with industry analysts, senior leaders from the Janssen Pharmaceutical Companies of Johnson& Johnson announced they anticipate submitting more than 10 new product filings and more than 25 significant brand line extensions by 2017.. With a unique model of innovation, the Pharmaceuticals
Below is a look at some of the headlines for companies that made news in the healthcare sector on May 23, 2013.{ nfg} Omeros Corporation announced its Investigational New Drug Application to evaluate OMS824 in Huntington's disease has been cleared by the U.S. Omeros plans to advance OMS824 into Phase 2 clinical trials for Huntington's disease next
Perosphere Inc. said that it has received U.S. Food and Drug Administration Investigational New Drug clearance to initiate clinical investigations of the safety and efficacy of PER977 to reverse the anticoagulant activity of unfractionated heparin, low molecular weight heparins, fondaparinux, and factor Xa- and IIa-inhibitors. Daiichi Sankyo Compan
Protalex, Inc., a clinical-stage biopharmaceutical company, announced that following a planned interim safety review by its independent Data Safety Monitoring Committee, the Company is continuing enrollment and increasing the dose for subjects in its multicenter Phase 1 b randomized, multiple-dose, dose-escalation study of PRTX-100 in combination..
Research and Markets Adds Report: BioPharmaceutical Industry in China- An In Depth Analysis of Multinational and Chinese Biopharma Companies, Industry Trends, Environment, Regulation, Market Drivers, Restraints, Opportunities and Challenges. Research and Markets has announced the addition of the updated "BioPharmaceutical Industry in China- An In D
Research and Markets has announced the addition of the " Generic Pharmaceuticals" report to their offering. Despite the Global Generic Pharmaceutical industry becoming increasingly competitive there are 42 vibrant companies across the World exploiting innovative, more profitable routes to market. Just published the Plimsoll Global Analysis- Generic
Sinovac Biotech Ltd., a leading provider of biopharmaceutical products in China, announced that Sinovac Beijing, the main operating subsidiary company of Sinovac, obtained the Certificate of Good Manufacturing Practices for Pharmaceutical Products from the China State and Food Administration for its proprietary vaccines, its Haidian district bulk..
Release date- 23052013- AMBRIDGE, Mass.,- Takeda Pharmaceutical Company Limited today announced the initiation of an international phase 3 clinical trial evaluating once a week MLN9708 in combination with lenalidomide and dexamethasone in patients with newly diagnosed multiple myeloma who are not candidates for transplant. The multi-center study wi
Agency Information Collection Activities; Announcement of Office of Management and Budget Approval; Guidance on Meetings With Industry and Investigators on the Research and Development of Tobacco Products. SUMMARY: The Food and Drug Administration is announcing that a collection of information entitled "Guidance on Meetings With Industry and...
